<div dir="ltr">Dear Farrokh,<div><br></div><div>Thanks a lot for the information. I'll come back to you later .</div><div><br></div><div>KP</div></div><div class="gmail_extra"><br><br><div class="gmail_quote">On Wed, Feb 5, 2014 at 1:33 AM, Farrokh Modabber <span dir="ltr"><<a href="mailto:fmodabber@dndi.org" target="_blank">fmodabber@dndi.org</a>></span> wrote:<br>
<blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex">
<div lang="EN-US" link="blue" vlink="purple">
<div>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1f497d">Dear KP,<u></u><u></u></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1f497d">Both leishmanin and BCG we used were produced at Pasteur Inst, Iran. Leishmanin is from a well characterized
<i>L. major</i> promastigotes. Dr Alimohammadian was in charge of leishmanin and he is cc’ed if you like to contact him. I am sure Ali knows about it too but I thought dr Alimohammadian might tell you the specifics or send you his SOP. There are several
BCG’s (Pasteur Institute Paris, Staten Institute Denmark, one from Japan, and others). We tested several and decided on the Pasteur Institute of Iran because of its moderate reactogenicity, cost and availability). The injection is 0.1 ml (if I remember correctly
containing about 10</span><sup><span style="font-size:16.0pt;font-family:"Calibri","sans-serif";color:#1f497d">5</span></sup><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1f497d"> /ml) i.d. usually in the forearm and read between
48-72 hrs later for induration using the ball-point method. We have also used autoclaved promastigotes(the first generation vaccine) as leishmanin and it also worked! <u></u><u></u></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1f497d">Hope you will get more specific info from other colleagues.
<u></u><u></u></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1f497d">Best regards,<u></u><u></u></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1f497d">Farrokh<u></u><u></u></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1f497d"><u></u> <u></u></span></p>
<p class="MsoNormal"><b><span style="font-size:10.0pt;font-family:"Tahoma","sans-serif"">From:</span></b><span style="font-size:10.0pt;font-family:"Tahoma","sans-serif""> Kwang-Poo Chang [mailto:<a href="mailto:kwangpoo.chang@rosalindfranklin.edu" target="_blank">kwangpoo.chang@rosalindfranklin.edu</a>]
<br>
<b>Sent:</b> Tuesday, February 04, 2014 10:57 AM<br>
<b>To:</b> Ali Khamesipour<br>
<b>Cc:</b> Farrokh Modabber; <a href="mailto:Leish-l@lineu.icb.usp.br" target="_blank">Leish-l@lineu.icb.usp.br</a><br>
<b>Subject:</b> Re: [Leish-l] Induction of LST positivity by BCG vaccination<u></u><u></u></span></p>
<p class="MsoNormal"><u></u> <u></u></p>
<div>
<p class="MsoNormal">Dear Ali,<u></u><u></u></p>
<div>
<p class="MsoNormal"><u></u> <u></u></p>
</div>
<div>
<p class="MsoNormal">Could you give me the information for the source of BCG used and also the protocol for preparing materials for the leishmanin test ? I recall the materials are either Leishmania promastigotes or Crithidia preserved in 1% phenol ? I could
be totally wrong. I don't remember the species and cell density or number, etc. Also, the volume and site of injection...........<u></u><u></u></p>
</div>
<div>
<p class="MsoNormal"><u></u> <u></u></p>
</div>
<div>
<p class="MsoNormal">Thank you in advance for your consideration of these requests.<u></u><u></u></p>
</div>
<div>
<p class="MsoNormal"><u></u> <u></u></p>
</div>
<div>
<p class="MsoNormal">KP<u></u><u></u></p>
</div>
</div>
<div>
<p class="MsoNormal" style="margin-bottom:12.0pt"><u></u> <u></u></p>
<div>
<p class="MsoNormal">On Fri, Jan 10, 2014 at 8:47 AM, Ali Khamesipour <<a href="mailto:khamesipour_ali@yahoo.com" target="_blank">khamesipour_ali@yahoo.com</a>> wrote:<u></u><u></u></p>
<div>
<div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif"">Dear All,<br>
Dr Modabber you should well remember that in the trials in Iran we had a degree of LST conversion in individuals who were originally LST negative (no response to leishmanin; no induration and no erythema), the control group received BCG, and a percent of them
converted to LST positive.<br>
All the best Ali <u></u><u></u></span></p>
<div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif""><u></u> <u></u></span></p>
</div>
<div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif""> <u></u><u></u></span></p>
</div>
<div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif"">Dr Ali Khamesipour<u></u><u></u></span></p>
</div>
<div>
<p class="MsoNormal" style="margin-bottom:12.0pt"><span style="font-family:"Helvetica","sans-serif""><u></u> <u></u></span></p>
<div>
<div>
<div>
<p class="MsoNormal"><span style="font-family:"Arial","sans-serif"">On Friday, January 10, 2014 11:22 AM, Farrokh Modabber <<a href="mailto:fmodabber@dndi.org" target="_blank">fmodabber@dndi.org</a>> wrote:</span><span style="font-family:"Helvetica","sans-serif""><u></u><u></u></span></p>
</div>
<div>
<div>
<div>
<div>
<div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif"">Dear Colleagues,<u></u><u></u></span></p>
</div>
<div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif"">I recall from Prof. Mayrinks studies, that BCG vaccination may convert leishmanin skin test in some volunteers who are LST-negative (MST-negative). The reactivity would gradually diminish
after a few months. Would appreciate any information on that and on Prof. Mayrink’s current email address.<u></u><u></u></span></p>
</div>
<div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif"">Many thanks,<u></u><u></u></span></p>
</div>
<div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif"">Farrokh Modabber<u></u><u></u></span></p>
</div>
</div>
<p class="MsoNormal"><span style="font-family:"Helvetica","sans-serif""><br>
<br>
--<br>
<i>This email was sent by <a href="http://icb.usp.br" target="_blank">icb.usp.br</a>
</i> ­­ <u></u><u></u></span></p>
</div>
</div>
<p class="MsoNormal" style="margin-bottom:12.0pt"><span style="font-family:"Helvetica","sans-serif""><br>
_______________________________________________<br>
Leish-l mailing list<br>
<a href="mailto:Leish-l@lineu.icb.usp.br" target="_blank">Leish-l@lineu.icb.usp.br</a><br>
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
<br>
--<br>
This email was sent by <a href="http://icb.usp.br" target="_blank">icb.usp.br</a><br>
<br>
<u></u><u></u></span></p>
</div>
</div>
</div>
</div>
</div>
<p class="MsoNormal"><br>
<br>
--<br>
<i>This email was sent by <a href="http://icb.usp.br" target="_blank">icb.usp.br</a>
</i> ­­ <u></u><u></u></p>
</div>
<p class="MsoNormal" style="margin-bottom:12.0pt"><br>
_______________________________________________<br>
Leish-l mailing list<br>
<a href="mailto:Leish-l@lineu.icb.usp.br" target="_blank">Leish-l@lineu.icb.usp.br</a><br>
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
<br>
--<br>
This email was sent by <a href="http://icb.usp.br" target="_blank">icb.usp.br</a><u></u><u></u></p>
</div>
<p class="MsoNormal"><u></u> <u></u></p>
</div>
</div>
</div>
</blockquote></div><br></div>